Nelfinavir Mesylate

甲磺酸奈非那韦

Report date: 2026/05/25 20:02:40
NME

Base Information

Drug NameNelfinavir Mesylate
Drug Alias Name奈非那韦甲磺酸萘非那韦ViraceptLY-312857AG-1343 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHuman immunodeficiency virus type 1 protease inhibitors
TargetsHuman immunodeficiency virus type 1 protease
Therapy Area/IndicationsLupus Erythematosus, SystemicPrimary MyelofibrosisUterine Cervical Incompetence +[10] 
Global Approved IndicationsHIV Infections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1997/03/14
Country/TerritoryUnited StatesEUMainland China +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesAgouron Pharmaceuticals Llc
China Registration ClassN/A

Develop Information

Active CompaniesAgouron Pharmaceuticals LlcUniversity of California IrvineJapan Tobacco (Hong Kong) Ltd +[5] 
Inactive CompaniesThe University Of Texas Health Science Center At HoustonThe University Of IowaNorthwell Health, Inc +[4] 
Active IndicationsPrimary MyelofibrosisHIV Infections
Inactive IndicationsLupus Erythematosus, SystemicUterine Cervical IncompetenceCarcinoma, Non-Small-Cell Lung +[8] 

Other Information

ATC CodeJ05AE04
Related LinksWikipediaDrugBankKEGG